Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aspira Pathlab & Diagnostics Ltd (ASPIRA) is currently trading at 143.34 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services. The company operates with an asset-light model but faces high operational costs which it is working to optimize. Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations. The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.
Over the past 52 weeks, Aspira Pathlab & Diagnostics Ltd has traded between a low of ₹49.00 and a high of ₹143.34. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aspira Pathlab & Diagnostics Ltd has a market capitalization of approximately 147.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aspira Pathlab & Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 147.54 Cr, Aspira Pathlab & Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aspira Pathlab & Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd is 61.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services.
The company operates with an asset-light model but faces high operational costs which it is working to optimize.
Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations.
The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.
Healthcare Services
Healthcare Service Provider
148 Cr
Low Risk
61.5
63.4
0.4
20.4
143.34
49.00
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
2
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
2
Bullish
5
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
167.80 | 176 Cr | 19.62 | 2.02 | 0.00 | 10.28 | 12.74 | 8.60 | ||
90.55 | 149 Cr | 62.72 | 2.63 | 0.00 | 5.93 | 8.44 | 0.00 | ||
143.34 | 148 Cr | 61.47 | 20.39 | 0.00 | 16.62 | 13.17 | 13.75 | ||
188.90 | 132 Cr | 60.91 | 5.14 | 0.00 | 5.87 | 8.80 | 3.00 | ||
75.25 | 131 Cr | 6.80 | 1.13 | 0.00 | 16.61 | 20.64 | 12.53 | ||
66.00 | 129 Cr | 25.68 | 2.46 | 0.00 | 9.53 | 9.10 | 0.00 | ||
68.50 | 103 Cr | 19.70 | 1.77 | 0.00 | 8.97 | 8.79 | 4.43 | ||
| Median: 7 Co. | — | 90.55 | 132 Cr | 25.68 | 2.46 | 0.00 | 9.53 | 9.10 | 4.43 |
Regulatory/Compliance Filing
Aspira Pathlab & Diagnostics: Jay Arvind Bhanushali acquired 1,424 equity shares (~0.01%) via open market between 2026-09-17 and 2026-09-24; post-holding 7,49,262 shares (7.28%).
AGM/EGM Notice
Aspira Pathlab & Diagnostics Ltd disclosed voting results and the consolidated Scrutinizer's Report for its 53rd AGM dated 25-09-2026; remote e-voting was held Sep 22-24, 2026 and five resolutions were passed.
AGM/EGM Notice
Aspira Pathlab & Diagnostics Ltd: Summary of proceedings and outcomes of 53rd AGM held on 2026-09-25; five resolutions transacted including reappointment and redesignation. Company reported FY2026 profit of INR 5.13 Lakhs vs INR 207.26 Lakhs prior year.
